Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. increased its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 9.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 240,216 shares of the company's stock after buying an additional 19,777 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.84% of Krystal Biotech worth $43,727,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in KRYS. CANADA LIFE ASSURANCE Co boosted its position in shares of Krystal Biotech by 80.7% in the first quarter. CANADA LIFE ASSURANCE Co now owns 3,128 shares of the company's stock worth $557,000 after acquiring an additional 1,397 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Krystal Biotech by 160.3% during the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company's stock valued at $28,000 after buying an additional 93 shares during the period. Jamison Private Wealth Management Inc. acquired a new stake in shares of Krystal Biotech during the 2nd quarter worth $28,000. AlphaMark Advisors LLC purchased a new position in shares of Krystal Biotech in the 2nd quarter worth $353,000. Finally, Blue Trust Inc. boosted its holdings in Krystal Biotech by 2,328.6% in the second quarter. Blue Trust Inc. now owns 170 shares of the company's stock valued at $30,000 after acquiring an additional 163 shares during the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

Krystal Biotech Trading Down 1.3 %

NASDAQ:KRYS traded down $2.51 on Monday, reaching $194.91. The stock had a trading volume of 257,555 shares, compared to its average volume of 323,901. The company has a 50-day moving average of $180.79 and a 200 day moving average of $184.11. The stock has a market cap of $5.61 billion, a P/E ratio of 110.12 and a beta of 0.82. Krystal Biotech, Inc. has a 12-month low of $100.98 and a 12-month high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, beating analysts' consensus estimates of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The firm had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. During the same quarter in the prior year, the business posted ($0.67) earnings per share. Krystal Biotech's revenue for the quarter was up 879.9% on a year-over-year basis. On average, equities analysts predict that Krystal Biotech, Inc. will post 2.97 EPS for the current year.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the sale, the insider now directly owns 1,500,882 shares of the company's stock, valued at approximately $296,814,424.32. This represents a 1.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 14.10% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on KRYS shares. Chardan Capital raised their price objective on Krystal Biotech from $153.00 to $208.00 and gave the stock a "buy" rating in a report on Monday, August 5th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Krystal Biotech in a research note on Thursday, August 29th. HC Wainwright reissued a "buy" rating and issued a $221.00 target price on shares of Krystal Biotech in a research note on Tuesday, November 5th. Stifel Nicolaus upped their price target on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a "buy" rating in a research report on Wednesday, September 11th. Finally, Evercore ISI raised their price objective on Krystal Biotech from $201.00 to $206.00 and gave the company an "outperform" rating in a research report on Monday, August 12th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $202.29.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).